Gilead Sciences Announces Executive Promotions
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, has decided to leave Gilead to pursue another opportunity.
Mr. Alton joined the company nearly 20 years ago and was the architect of its access program, which has enabled Gilead’s HIV medicines to reach more than 11 million people in the developing world. He has helped shape the organization in a number of executive positions, including as general counsel, and more recently, leading the company’s international commercial operations and corporate affairs groups. Prior to joining Gilead, he was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships, and corporate finance transactions for healthcare and information technology companies. Mr. Alton received a bachelor's degree from the University of California, Berkeley, and holds a JD from Stanford University.
“Gregg has a deep and broad understanding of the company and an unparalleled commitment to enabling access to our medicines for millions of people in both the developed and developing world,” said John F. Milligan, PhD, President and Chief Executive Officer of Gilead. “Bringing together into one organization a number of groups – including Access Operations & Emerging Markets, Public Affairs & Advocacy, Government Affairs, Medical Affairs, Digital Patient Solutions and the company’s commercial operations in certain countries in Asia – will help us better serve patients.”
Dr. Brainard joined Gilead in 2010. She has extensive training and experience in immunology, infectious diseases and drug development. Under her leadership, Gilead received regulatory approval of four chronic hepatitis C virus (HCV) therapies in a period of less than four years. She was promoted to Vice President, Clinical Research, Liver Diseases, in 2015. Dr. Brainard received a bachelor’s degree from Brown University, holds an MD from Tulane University School of Medicine, and completed her residency and fellowship in internal medicine and infectious diseases at Harvard University. Dr. Brainard trained as an infectious diseases physician at Massachusetts General Hospital and was on faculty at Harvard Medical School, where her NIH-funded research focused on translational models and T-cell trafficking in HIV infection. In addition to her clinical and research activities in Boston, she helped establish an immunology laboratory and train researchers at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal in Durban, South Africa.
“Diana is an astute, knowledgeable and experienced clinician and researcher with broad expertise across the field of infectious diseases. She played an instrumental role in the rapid clinical development and approval of Gilead’s HCV medicines,” said John McHutchison, MD, Chief Scientific Officer and Head of Research and Development. “The vision and leadership that she brings to this role will enable Gilead to continue to innovate, and advance new therapies for people with HIV and other emerging viruses.”
Dr. Cheng joined Gilead in 1999 to lead the company’s development-stage programs in HIV/AIDS. He received additional responsibility for the company’s Development Operations organization in 2009 and was named Executive Vice President in 2015. Dr. Cheng was appointed Chief Medical Officer in March.
“During his time at Gilead, Andrew played a definitive role in bringing forward new medicines that transformed the lives of millions of people with serious illnesses,” said Dr. Milligan. “Andrew played an especially critical part in advancing our portfolio of HIV products, and we’re extremely grateful for his many contributions and wish him all the best in the future. We are very pleased that Diana will lead this important therapeutic area for us going forward, as we seek to advance our next generation of HIV medicines, including potential options for prevention and perhaps one day a cure.”
Dr. Cheng will remain at Gilead until September 7 to help with the transition of his duties. Mr. Alton and Dr. Brainard will take on their new roles effective immediately.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties, and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792
Amy Flood, 650-522-5643
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies15.11.2018 14:30 | Tiedote
Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer. Specifically, these targets are enzymes within the helicase and histone acetyltransferase (HAT) families that when dysregulated have been linked to the development of cancers that currently lack therapeutic options. “Boehringer Ingelheim’s collaboration with Epizyme furthers our strategic vision to profoundly impact the oncology treatment landscape by enabling a new generation of precision medicines,” said Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research, Boehringer Ingelheim. “We are excited to launch this partnership with Epizyme and to work together with them to advance epigenetic inhibitors that have the potential to transform the lives of patients and help win t
New Direct-to-home Satellite TV Bouquet for the Former Yugoslavian Countries from Telekom Srbija and SES15.11.2018 13:34 | Tiedote
Viewers in Serbia, Bosnia and Herzegovina, and Montenegro will soon have access to new content delivered by Telekom Srbija from SES’ key orbital location at 23.5 degrees East. SES announced today that the main telecommunication operator in Serbia has signed a multi-year and multi-transponder contract for service on its Astra satellite to launch Telekom Srbija’s new Direct-to-Home (DTH) platform which will start broadcasting in all three countries simultaneously mid-December. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005405/en/ New Direct-to-home Satellite TV Bouquet for the Former Yugoslavian Countries from Telekom Srbija and SES (Photo: Business Wire) The new DTH platform will enable Telekom Srbija to broadcast more than 150 channels, including up to 30 in High Definition (HD). All Serbian public television channels will also be available on the platform, bringing a complete selection of content to viewers in the
Great Eastern Energy Corporation to Venture into Shale Gas Exploration15.11.2018 13:18 | Tiedote
Great Eastern Energy Corporation Limited (LSE: GEEC), the fully integrated, leading Indian Coal Bed Methane (“CBM”) Company, today announced an upgrade in its resources at its Raniganj (South) block, which has been provided by the independent reserve engineers, Advance Resources International, Inc. (“ARI”). The Government of India has permitted exploration and exploitation of all types of hydrocarbons including shale resources under the existing CBM Contracts. ARI has made the following assessment of the CBM and Shale resources in the Raniganj (South) block: Classification Category SHALE Resources (TCF) CBM Resources (TCF) Total Resources (TCF) Original-Gas-In-Place (“OGIP”) Low Estimate 1.40 2.62 4.02 Best Estimate 3.51 6.13 High Estimate 6.63 9.25 Classification Resource Type Category Gross Recoverable Gas (BCF) Total Future Net Revenues ($ Million) Undiscounted Discounted at 10% per annum Reserves CBM 1P 336.00 $2,037.00 $675.50 2P 510.80 $3,073.00 $965.90 3P 594.70 $3,535.10 $1,076
MultiBank Group Expands Across Europe Making It One of the Largest Financial Derivatives Companies Worldwide15.11.2018 12:46 | Tiedote
In December 2017, MultiBank Group announced the launch of its Asset Management business and the establishment of its European headquarter in Frankfurt, Germany. Since then, the Group’s asset management business has taken off, while the performance of the MultiBank Index linked Note, listed on the Frankfurt Stock Exchange, has reached an all time high at EUR 1,357 today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005376/en/ MultiBank Group Global Presence. (Photo: Business Wire) As such, with the expansion in Europe, the Group has now offices in Hong Kong, Frankfurt, Sydney, Vienna, Barcelona, Beijing, Guangzhou, Ho Chi Minh City, Los Angeles, Cyprus, the British Virgin Islands and the Cayman Islands, with further prompt expansion anticipated in Dubai, London, Santiago (Chile) and Jakarta (Indonesia). This will make MultiBank Group one of the largest online financial derivatives providers with over 310,000 clients a
GSMA Welcomes Germany’s 5G Spectrum Award, but Cautions against Unnecessary Conditions15.11.2018 11:00 | Tiedote
The GSMA today welcomed the German government’s decision to release the entire 3.4 to 3.8 GHz band (C-Band), essential for the future development of 5G services globally. Making available all of the spectrum in this critical band for 5G, in a timely manner, shows Germany’s commitment to European and global 5G leadership. However, the GSMA warns that some of the currently proposed conditions on the allocation of these vital frequencies may slow Germany’s 5G future. Ultra-fast 5G networks will form the foundation of the world’s digital economy, supporting a wide variety of industry sectors. Imposing unnecessary conditions that limit mobile operators’ ability and potential to deliver 5G creates a risk for all, industries and citizens alike. “The C-Band is the most vital frequency band for 5G. Germany is demonstrating 5G leadership in the timely release of this vital spectrum, but risks undercutting its 5G future with unnecessary obligations,” said Mats Granryd, Director General, GSMA. “Sp
Entersekt Sets Sights on the Nordics15.11.2018 11:00 | Tiedote
Entersekt, an innovator in mobile-first fintech solutions, today announced its entry into the competitive Nordic market. The identity and payments enablement provider serves banks and other enterprises operating in 45 countries. Entersekt’s interest in Scandinavia derives from its openness to digital banking and payments innovation. Digitization may be transforming business in every corner of the world, but few regions have experienced the wholesale change in consumer payments behaviour that the Nordics have. While governments, central banks, and the banking industry as a whole have pushed a cashless agenda for several years now, many point to Nordic consumers’ enthusiastic adoption of cashless transacting as the true driver behind the boom in digital payments. Consumers in the region have never been hidebound to payments innovation, as smart card penetration rates demonstrated years ago. Payments-ready smartphones are, of course, everywhere and the retail NFC infrastructure is superb.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme